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Effective vaccination strategies for infectious diseases take into account the induction, long-term maintenance and recall of memory T-cell
populations. To understand the immunological cross-talk within the mucosal compartments, we compared intranasal to vaginal immunization and
demonstrated that vaginal infection of BALB/c mice with influenza A virus provides protective mucosal immunity against both homosubtypic and
heterosubtypic virus challenge in the respiratory tract. We found that, prior to the viral challenge, in vaginally primed mice, antigen-specific CD8+
T cells were not detected in the lung airways and levels of serum antibodies were lower than those observed in intranasally immunized mice.
However, following pulmonary challenge, NP147-specific CD8+ T cells were recruited and amplified in vaginally primed mice to the same extent
as those in intranasally primed mice. Thus, the long-term memory immune response elicited by vaginal immunization with influenza virus is
efficiently recalled and offers reasonable protection against infection in the respiratory tract.
© 2006 Elsevier Inc. All rights reserved.Keywords: Influenza A virus; Heterosubtypic immunity; Memory T-cell responses; Vaginal immunizationIntroduction
Establishing both strong mucosal and systemic immune
responses is important for the prevention of most mucosa-
contracted infections. Indeed, the common mucosal immune
system allows immunological cross-talk within different
mucosal effector sites, increasing the options for vaccination
(Bienestock et al., 1992; McDermott and Bienenstock, 1979;
Staats et al., 1994). Intranasal immunization is known to
efficiently stimulate humoral and cell-mediated immune
responses at both the systemic and mucosal levels. Further-
more, nasal immunization is an effective route of cross-
immunization within the integrated mucosal immune system⁎ Corresponding author. Fax: +39 06 49902082.
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doi:10.1016/j.virol.2006.12.001since it induces long-term specific immunity in the genital
tract (Dupuy et al., 1999; Ferko et al., 2001; Gallichan and
Rosenthal, 1996, 1998; Gherardi et al., 2003; Klavinskis et al.,
1999; Muster et al., 1995). In contrast, limited information is
available concerning immune trafficking to the respiratory
tract upon vaginal immunization.
We recently showed that progesterone-treated BALB/c mice
support the replication of influenza A viruses in vaginal tissues
(Garulli et al., 2004). A single inoculation of an influenza virus
via the vaginal route induced specific humoral and cellular
immune responses both in the spleen and in regional lymph
nodes. Moreover, upon vaginal immunization, mice generated
long-term virus-specific memory cytotoxic T lymphocytes
(CTLs) in the spleen and in the mucosal lymph nodes that
drain the genital tract, as detected by a rapid recall of effector
CTLs on re-exposure to the antigen. However, the extent to
which such memory responses afford protection from challenge
with pathogens remains unknown.
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intranasal immunization to protect against pulmonary infection
of homosubtypic or heterosubtypic influenza A virus. Our data
show that vaginal immunization with influenza virus effectively
primes long-term, sustained protective immune responses in the
pulmonary organs, albeit to a lesser extent than intranasal
priming.
Results
Induction of local and systemic memory CTLs cross-reactive
with viruses of different subtypes following vaginal infection
with influenza A virus
In our previous study (Garulli et al., 2004), we showed that
vaginal immunization with a recombinant influenza virus
bearing an HIV-1 T-cell epitope (Flu/P18IIIB) induced a
vigorous immune response at both mucosal and systemic levels
against influenza viral and the HIV-1 epitopes. Here, we asked
whether the subtype cross-reactive CD8+ T-cell responses can
be induced in spleen and iliac lymph nodes (ILN) by vaginal
infection of mice with influenza A viruses. Groups of BALB/c
mice were first vaginally primed by infection with 3×105 PFU
of X31 virus (H3N2). Six months after priming, these mice, and
age-matched control mice, were vaginally infected again with
106 PFU of the serologically distinct WSN virus (H1N1) that
shares the NP147 immunodominant epitope (H-2Kd) with the
X31 virus. Mice were sacrificed either 3 days or 5 days
postinfection and their regional lymph nodes and spleens
assayed for NP-specific CTL activity. To achieve this, ILN-
derived lymphocytes, cultured in vitro for 3 days without
exogenous antigen, and splenocytes that had undergone
antigen-specific stimulation for 6 days were examined for
their ability to lyse 51Cr-labeled P815 target cells pulsed withFig. 1. Long-lived specific memory CTL activity in mice vaginally infected with X31
X31 virus and 6 months later infected with 106 PFU of WSN virus. ILN (A) and splee
ILN were cultured without antigen stimulation for 3 days before being tested in a CT
peptide-loaded stimulators before being examined for CTL activity. CTLs were assa
measured at an effector-to-target ratio of 50:1 are shown.the peptide NP147. One characteristic example of 51Cr release
data at an effector-to-target ratio of 50 to 1 is shown in Fig. 1. In
the control (unprimed) mice, the CTL response to WSN virus in
ILN-derived cells (Fig. 1A) was detectable on day 5 but not day
3 postinfection and was barely detectable in splenocytes at the
day 5 time point (Fig. 1B). By contrast, the CTL response of
X31-primed mice measured after WSN challenge was substan-
tially higher than that of the control, unprimed mice in both the
ILN-derived cells and splenocytes, on day 3 and day 5
postinfection. The effector cells that lysed peptide-pulsed
MHC-compatible target cells exhibited only background levels
of lytic activity against unpulsed P815 target cells or
allospecific EL4 cells (data not shown).
Thus, vaginal immunization with influenza virus resulted in
efficient induction and long-term maintenance of virus cross-
reactive NP-specific CTLs in local draining lymph nodes and
the spleen.
Long-lived memory CD8+ T-cell responses to heterosubtypic
influenza A virus in the draining lymph nodes of the respiratory
tract of vaginally primed mice following intranasal challenge
To understand the cross-talk between the two different
mucosal compartments, we next examined immune trafficking
to the respiratory organs in mice vaginally immunized with
influenza virus. To this end, we compared the induction and
maintenance of long-term memory NP147-specific CD8+ T
cells in mice primed by the vaginal route relative to that in mice
primed by the intranasal route. Freshly isolated NP147-specific
CD8+ T lymphocytes in the mediastinal lymph nodes (MLN)
that drain the respiratory tract were assayed for reactivity with
an NP147/Kd tetramer in groups of naive and immune
(intranasally or vaginally primed) mice following intranasal
challenge with WSN virus (Flynn et al., 1998). We found that,virus. Groups of five BALB/c mice were vaginally infected with 3×105 PFU of
ns (B) were removed 3 or 5 days after the vaginal infection with WSN virus. The
L assay. Spleen cells were stimulated for 6 days in vitro with irradiated NP147
yed with NP147 peptide-pulsed P815 cells as targets. Mean lysis values (±SD)
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lymphocytes in the MLN of WSN-infected mice were induced
at low levels on day 3 and slightly higher levels by day 5
postinfection (Fig. 2A, lower panel). Mice either vaginally or
intranasally immunized 4 months previously with X31 and then
intranasally challenged with WSN virus showed an increase in
NP-specific CD8+ T cells by day 3 (∼20,000–25,000 cells/
mouse) and reached high levels by day 5 post-challenge
(∼120,000 cells/mouse) with similar kinetics in both primed
groups (Fig. 2B). These cells represented 2% and 7–7.5% of
CD8+ T cells in the draining lymph nodes on day 3 and on day
5, respectively (Fig. 2A).Fig. 2. Subtype cross-reactive CD8+ T cells in MLN of mice. Groups of seven
mice were either vaginally (vag) or intranasally (i.n.) infected with 3×105 PFU
of X31 virus. Four months later, they were intranasally infected with 106 PFU of
WSN virus. On day 3 or day 5 after challenge, the mice were sacrificed. Freshly
isolated MLN were enriched for the CD8+ T lymphocytes, as described in
Materials and methods, before undergoing staining with tetramer specific for
Flu-NP147/Kd and with anti-CD8 antibody. The percentages of tetramer-
positive CD8+ T cells are indicated in the upper right corner of each panel (A).
Data are representative of one of three independent experiments. (B) The
absolute numbers of tetramer-positive cells (±SD) in the MLN per mouse.The MLN-derived lymphocytes from all groups of mice
were also cultured in vitro for 3 days and functionally tested for
CTL activity (Fig. 3). Both vaginal and intranasal X31
immunization stimulated effectors in MLN at early time points
post-challenge, as shown by high levels of CTL-mediated
killing of NP147-pulsed P815 target cells (86% and 78% mean
specific lysis, respectively, at an effector-to-target ratio of 50 to
1) (Fig. 3A). As expected, specific CTL activity was detected in
naive mice on day 5. The CTL-mediated lysis was MHC-
restricted and peptide-specific because unloaded P815 and
allogeneic EL4 target cells were not killed (data not shown).
Splenocytes from the same groups of mice were also examined
for NP147-specific CTL activity (Fig. 3B). Both routes of
immunization induced a systemic memory response, as revealed
by substantial cytotoxicity on day 3 compared to very little
activity on day 3 or day 5 in unprimed mice.
These results indicate that vaginal priming elicited long-term
NP147-specific CTL memory responses in mice that were
rapidly recalled at the lymphoid tissues draining the distant
mucosal sites. In addition, the magnitude of the secondary
response was comparable to that observed in intranasally
primed mice.
Recruitment of memory CD8+ T lymphocytes in the lung
airways upon intranasal challenge in pre-immune mice
An effective cellular immune response of immunized
animals to infection requires rapid recruitment and activation
of memory T cells to the site of infection. In particular, the
homing of profuse numbers of cytotoxic effectors to the infected
lung epithelium is crucial for their protective role during
influenza virus infection. We therefore evaluated the recruit-
ment of effector T cells to the respiratory site upon viral
challenge of mice that had been vaginally or intranasally
immunized. We quantitatively assayed the effector CD8+ T-cell
population in the lung airways of primed mice for NP147 T-cell
epitope specificity 5 days after challenging them with WSN
virus. A representative experiment is shown in Fig. 4.
Appreciably more NP147-specific CD8+ T lymphocytes were
obtained from the bronchoalveolar lavage (BAL) of both groups
of pre-immune mice (∼7000–10,000 cells/mouse) relative to
those obtained from unimmunized mice (∼300). These cells
comprised ∼50–55% of all CD8+ T cells in the lung airways.
Interestingly, more CD8+ T lymphocytes were consistently
found at this time in the vaginally primed mice as compared to
the intranasally primed mice.
CD4+ and CD8+ memory T cells are known to persist for
several months in secondary lymphoid and nonlymphoid
tissues following viral infection in mice (Hogan et al., 2001a;
Marshall et al., 2001; Masopust et al., 2001; Ostler et al.,
2001). However, the memory T-cell pool in the lungs of mice
which have had respiratory virus infections disappears over
time in parallel with the decline in protective cellular immunity
(Hogan et al., 2001a, 2001b; Kundig et al., 1996). To test the
longevity of memory CD8+ T cells in the lungs of mice that
had been either vaginally or intranasally primed and then
intranasally challenged, we quantified the NP147 antigen-
Fig. 3. CTL activity in MLN and spleen after secondary infection with heterosubtypic influenza Avirus. Four months after being either vaginally or intranasally primed
with 3×105 PFU of X31 virus, mice were intranasally infected with 106 PFU of WSN virus. On day 3 or day 5 after this challenge, the mice were sacrificed. The MLN
were cultured without antigen stimulation for 3 days prior to being subjected to a 51Cr-release assay (A). Spleen cells were stimulated for 6 days in vitro with irradiated
peptide-loaded stimulators and then examined for CTL activity against peptide-coated target cells (B). Effector-to-target ratios were 50:1. Lysis of unpulsed P815
target cells and allogeneic EL4 target cells are shown. The data are mean percentages of specific lysis for triplicate samples; standard deviations were <5%.
Fig. 4. Quantification of NP147-specific CD8+ T cells isolated from mouse
lung airways during the acute phase. Groups of seven mice were either
vaginally or intranasally infected with 3×105 PFU of X31 virus. Four months
later, they were intranasally infected with 106 PFU of WSN virus. Five days
post-challenge, the BAL populations collected from each group of mice were
examined by flow cytometry for surface staining with anti-CD8 and the Flu-
NP147Kd tetramer (A). The values shown are representative percentages of CD8
+ T cells (from three experiments) that were tetramer-positive. (B) The absolute
numbers of tetramer-positive cells (±SD) in the BAL per mouse.
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intranasal challenge. As shown in Fig. 5, higher numbers of
NP147 antigen-specific T cells were detected in the intrana-
sally than in the vaginally primed mice, although the
percentage of antigen-specific CD8+ T cells in the lung
airways was similar. We also detected approximately the same
percentage of NP147 antigen-specific T cells, with substan-
tially decreased numbers, 60 days after the intranasal challenge
(data not shown). Analysis of the CD8+ T-cell population in
the lung airways of X31-primed mice before WSN virus
challenge showed that approximately 25% of the CD8+ T cells
in the BAL of intranasally infected mice were specific for the
NP147/Kd epitope (∼1000 cells/mouse) 32 days post priming
(Fig. 5A), whereas the BAL of vaginally infected mice yielded
undetectable levels of CD8+ T cells.
These results demonstrate a rapid and vigorous antigen-
specific T-cell increase in lymphoid tissues and BAL in the early
acute phase that follows intranasal challenge of vaginally
primed mice. The data further show that a secondary infection
via the intranasal route is needed to relocate antigen-specific T
cells to the lung airways.
Humoral immune responses
We also examined the efficacy of vaginal versus intranasal
immunization to induce an influenza-specific antibody response
in mice. Three months after immunizing the mice, we measured
IgG in the sera and both IgG and IgA in the BAL and vaginal
washes from these mice by using an ELISA. Serum IgG
production was significantly higher in intranasally immunized
mice than in mice immunized vaginally (Fig. 6A). We also
measured the hemagglutination inhibition antibodies in serum
samples and found an eight-fold difference: 1:640 for intranasal
immunization versus 1:80 for vaginal immunization. IgG and
IgA antibody levels were also lower in both the BAL and
vaginal washes from vaginally immunized mice compared to
those from intranasally immunized animals (Fig. 6B).
Fig. 5. Quantification of NP147-specific CD8+ T cells isolated from mouse lung
airways during the memory phase. Groups of seven mice were either vaginally
or intranasally infected with 3×105 PFU of X31 virus. Four months later, they
were intranasally infected with 106 PFU of WSN virus. Thirty-two days post-
challenge, the BAL populations collected from each group of mice were
examined by flow cytometry for surface staining with anti-CD8 and the Flu-
NP147Kd tetramer (A). The values shown are representative percentages of CD8
+ T cells (from three experiments) that were tetramer-positive. (B) The absolute
numbers of tetramer-positive cells (±SD) in the BAL per mouse.
Fig. 6. Humoral immune responses. Samples (sera, trachea-lung washes, and
vaginal washes) from mice (n=5) were obtained 3 months after the mice were
either vaginally or intranasally infected with X31 virus. Influenza-specific IgG
and IgA in the samples of individual mice were detected by ELISA, as described
in Materials and methods. The values shown represent the mean (±SD) of the
end-point ELISA antibody titer (A) or the mean absorbance (±SD) of 1:2 diluted
lavages (B). At these dilutions, the absorbance values for control samples (i.e.,
samples from uninfected animals) were <0.03.
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elicits a better antibody response than does vaginal
immunization.
Protection against lethal challenge with homosubtypic and
heterosubtypic influenza viruses in vaginally or intranasally
immunized mice
Immunocompetent mice that have recovered from intranasal
infection with influenza virus exhibit a very high level of
sterilizing immunity to homologous viral challenge (Couch and
Kasel, 1983; Murphy and Webster, 1996), but show only partialprotection against an influenza virus of a different subtype (i.e.,
heterosubtypic immunity) (Gerhard et al., 1996; Liang et al.,
1994). To compare the extent of homosubtypic and hetero-
subtypic protection in vaginally or intranasally immunized
mice, we intranasally challenged groups of mice with lethal
doses of WSN virus 3 months after they were immunized by
one of these two routes. In the homosubtypic challenge
experiments (i.e., immunization with WSN and challenge
with 100 MLD50 of WSN), every unimmunized control mouse
died, whereas both intranasal and vaginal immunization
provided complete protection (Fig. 7A). Of note, transient
Fig. 7. Survival after challenge of primed BALB/c mice with homologous or heterologous influenza virus. BALB/c mice were immunized with WSN virus by vaginal
(106 PFU) or intranasal infection (5×102 PFU). Three months later, they were intranasally challenged with 100 MLD50 of the homologous virus. Mortality was
monitored daily for at least 30 days (A). Mice were immunized with X31 virus by the vaginal (3×105 PFU) or intranasal route (3×105 PFU). Three months later, they
were intranasally challenged with 10 MLD50 or 20 MLD50 of WSN virus (B). Mortality was monitored daily for at least 30 days.
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shown).
In the heterosubtypic challenge experiments, mice were first
immunized with X31 virus either vaginally or intranasally and
then challenged with either 10 or 20 MLD50 of WSN virus.
With the challenge dose of 10 MLD50, both immunization
routes provided complete protection (Fig. 7B), although weight
loss among vaginally immunized mice was greater than that
among mice immunized intranasally (data not shown). With the
challenge dose of 20 MLD50, however, only 30% of mice
immunized vaginally survived, whereas none of the mice
immunized nasally died. These results show that, although the
extent of protective immunity against lethal nasal challenge
following vaginal immunization is not as high as that achieved
with intranasal immunization, vaginal immunization does
provide substantial protective immunity in pulmonary organs.
Discussion
Here, we have demonstrated that vaginal immunization of
BALB/c mice with influenza virus can induce long-lasting
memory T-cell populations that efficiently relocate to distant
sites and provide protection against viral challenge in the
respiratory tract.Immunity induced by influenza virus infection protects the
host against the same strain of influenza virus. Such protection
is long-lasting and normally attributed to neutralizing antibodies
specific for the viral membrane glycoproteins hemagglutinin
and neuraminidase. Several studies have demonstrated the role
of cross-reactive CTLs in heterosubtypic protection and
recovery from infection (Epstein et al., 1998; Gerhard et al.,
1996; Liang et al., 1994; Nguyen et al., 1999; Taylor and
Askonas, 1986; Ulmer et al., 1993; Wraith et al., 1987; Yewdell
et al., 1985). However, recent studies have shown that B cells in
addition to CD8+ T cells are important for recovery from
infection (Gerhard et al., 1996; Nguyen et al., 2001; Tumpey et
al., 2001). Nguyen et al. (2001) demonstrated that B cell-, but
not CD8+ T cell-deficient mice fail to develop heterosubtypic
immunity against lethal infection with influenza A virus. They
suggest that subtype cross-reactive antibodies in immune mice
are the predominant effectors in limiting infection early after
challenge, whereas the induction of subtype-specific neutraliz-
ing antibodies is responsible for virus clearance and complete
host recovery. In our study, mice primed intranasally with X31
virus were completely protected against lethal infection even
with 20 MLD50 of WSN virus. On the other hand, vaginal
immunization provided only partial protection under these
conditions. We found that high levels of heterosubtypic CD8+ T
280 B. Garulli et al. / Virology 361 (2007) 274–282lymphocytes were detected in lung lavages and mucosa-
associated lymphoid tissues draining the respiratory tract of
mice primed vaginally with X31 virus upon intranasal challenge
4 months later (Figs. 2, 3). By contrast, virus-specific antibodies
were found at lower levels in mice primed vaginally (Fig. 6),
suggesting a possible correlation with the reduced extent of
cross-protection achieved.
Recent studies indicate that memory T cells comprise distinct
subpopulations of “central” memory and “effector” memory
cells that are characterized by different homing capacities and
effector functions (Kim et al., 1999; Sallusto et al., 2004).
Hogan et al. (2001a, 2001b) found that large populations of
Sendai and influenza virus-specific CD4+ and CD8+ memory T
cells remain not only in lymphoid organs, such as spleen and
lymph nodes, but also in nonlymphoid tissues following
recovery from a respiratory virus infection. These “peripheral”
memory T cells in the lung, designated effector memory T cells,
can mediate an immediate response to infection. However, their
numbers decline over time, correlating with the control of a
pulmonary infection. Here, we showed that antigen-specific
CD8+ T cells are present in the lung airways 1 month after
intranasal infection, but are undetectable following vaginal
infection (Fig. 5). Thus, the reduced protection observed upon
challenge with the 20 MLD50 of WSN virus in vaginally
immunized mice (Fig. 7B) may be attributable to a lack of
memory CD8+ T cells in the lung airways prior to viral
infection, in addition to lower levels of antibodies (Fig. 6).
In conclusion, we have shown that vaginal immunization
induces fully functional memory T cells that are efficiently and
rapidly recruited to distant nonlymphoid tissues following an
influenza virus infection of lungs. Our findings demonstrate that
a substantial protective effect of both mucosal and systemic
immunity can be achieved upon vaginal infection with influenza
virus. These findings are remarkable when we consider that the
vaginal inoculation of BALB/c mice with doses of WSN virus
that would be lethal by the intranasal route was well tolerated,
producing no obvious signs of illness or distress. In summary,
the newfound ability of influenza virus to induce both mucosal
and systemic immunity following vaginal infection could prove
to be a useful tool to further dissect the mechanisms involved in
complex immunologic phenomena, such as cross-talk among
different mucosal compartments.
Materials and methods
Viruses and mice
Influenza A viruses A/WSN/33 (WSN; H1N1) and X31 (a
reassortant between A/Hong Kong/1/68 and A/PR/8/34; H3N2)
were grown in embryonated eggs. Inbred, female BALB/c mice
(6–8 weeks) were purchased from Charles River, Calco, Italy
and maintained on a 12-h light/dark cycle.
Peptide and MHC tetrameric reagents
The H-2Kd-binding influenza A virus nucleoprotein peptide
NP147–155 (NP147 peptide, TYQRTRALV) (Bodmer et al.,1988) and the MHC class I-peptide tetramer Flu-NP147/Kd
conjugated to R-Phycoerythrin (PE) were synthesized by
Beckman Coulter (San Diego, CA 92121, USA).
Immunization and challenge of mice
Mice were lightly anesthetized with Avertin (2,2,2-tribro-
moethanol) before being intranasally infected with nonlethal
doses of influenza virus (3×105 PFU of X31 virus or 5×102
PFU of WSN virus) to prime for long-term memory. For vaginal
infection, groups of mice were subcutaneously injected with
3 mg of progesterone (Depo-Provera; Pharmacia and Upjohn)
(Garulli et al., 2004). Five days later, they were vaginally
infected with 3×105 PFU/10 μl of X31 virus, known to be free
of bacteria and endotoxin. For virus challenges, anesthetized
mice were intranasally infected with 10 or 20 MLD50 (dose
required to kill 50% of infected mice) of WSN virus
(MLD50=10
3 PFU), resuspended in 30 μl of PBS.
Isolation of lymphocytic populations
Inflammatory cells were collected from the BAL of infected
mice, adsorbed to plastic petri dishes for 60 min at 37 °C to
remove macrophages, and then directly subjected to tetramer
staining (Allan et al., 1990). ILN and MLN lymph nodes were
isolated and passaged through a sterile mesh screen to generate
single-cell suspensions. Viable cells were counted using trypan
blue dye exclusion, suspended in RPMI 1640 medium
supplemented with 10% FCS, 0.1 mM nonessential amino
acids, 1 mM sodium pyruvate, 5×10−5 M 2-mercaptoethanol,
2 mM glutamine, and 10 U/ml of rIL-2 (Roche Diagnostics),
and cultured for 3 days without exogenous antigen before being
tested in a 51Cr release assay. For ex vivo analysis of antigen-
specific T cells, the freshly isolated MLN population was
enriched for CD8+ T cells by treatment with monoclonal
antibodies (Mabs) to CD4 (GK1.5) and MHC class II (TIB120)
followed by sheep anti-mouse and sheep anti-rat Dynabeads
(Dynal A.S., Oslo, Norvay) (Flynn et al., 1998).
Secondary in vitro CTL effector populations were obtained
from infected mouse spleen. Erythrocyte-depleted splenic
lymphocytes were restimulated in vitro using gamma-irradiated
(3000 rads) peptide-loaded normal syngeneic spleen cells at
37 °C and 10% CO2, in RPMI 1640 medium supplemented as
described above. 10 U/ml of rIL-2 was added 3 days
poststimulation. On day 6, effector cells were harvested and
washed in culture medium before being tested in a 51Cr release
assay.
MHC tetrameric analysis
Macrophage-depleted BAL lymphocyte populations and
enriched CD8+ T cells from freshly isolated MLN were
stained with a rat anti-mouse CD8-FITC Mab (Pharmingen)
and the tetramer Flu-NP147/Kd, conjugated to PE, for 1 h
(Flynn et al., 1998; Murali-Krishna et al., 1998). Samples were
examined by FACScan flow cytometry, and the data analyzed
using CellQuest software (Becton-Dickinson Immunocytome-
281B. Garulli et al. / Virology 361 (2007) 274–282try Systems). The absolute number of tetramer-positive cells
was calculated using the percentage of tetramer-positive cells
among the total live cell gate and the number of cells
isolated per mouse in each tissue as indicated by trypan blue
staining.
Chromium release assays
Secondary in vitro cytotoxic effector populations were tested
with peptide-loaded P815 cells (H-2d) as targets in a standard
6 h 51Cr release assay. For peptide pulsing, P815 cells were
incubated with NP147 peptide (10−6 M) during 51Cr labeling
and then washed three times before use. To determine the H2
restriction, EL4 cells (lymphoma cells of C57BL/6 mice (MHC-
H2b)) were used as targets in the cytotoxicity assay. 51Cr-
labeled target cells were incubated with effector cells at the
indicated effector/target ratios. The amount of 51Cr released was
determined by gamma counting, and the percent specific lysis
was calculated from triplicate samples as follows: [(experi-
mental cpm− spontaneous cpm) / (maximal cpm− spontaneous
cpm)]×100. Spontaneous release was determined from target
cells incubated in the absence of effector cells and was <5% in
all experiments.
Measurement of antibody responses to the priming virus
Antibody titers to influenza virus in serum, BAL, and
vaginal washes were determined by standard enzyme-linked
immunosorbent assays (ELISA) (Webster et al., 1983). Vaginal
washes were collected from immune mice on day 5 after
progesterone treatment by lavaging the mice twice with 50 μl of
PBS. Immunoglobulins were extracted sequentially from
vaginal mucus into three separate volumes of 100 μl of PBS,
according to the method of Parr et al. (1998). For ELISA, a 96-
well microtiter plate (Nunc-Immuno™) was coated with the
appropriately diluted X31 virus in PBS (pH 7.4) for 4 h at room
temperature. Plates were then washed and incubated with serial
twofold dilutions of duplicate samples in PBS containing 0.5%
BSA overnight at 4 °C. The following day, the plates were
washed three additional times before being incubated for 1 h
with alkaline phosphatase-conjugated goat antimouse IgG
antibodies (Southern Biotechnology Associates) at room
temperature. After three additional washes, the plates were
then incubated with p-nitrophenyl phosphate (Sigma) for 1 h at
room temperature. Absorbance was read at 405 nm wavelength
with a microplate reader (BioRad). Serum hemagglutination
inhibition (HAI) titres were measured according to standard
procedures (Noble et al., 1977).
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